WMIC

Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, September 11, 2023

SEATTLE, WA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of preclinical data from two independent studies at the World Molecular Imaging Congress (WMIC) 2023, held on September 5-9, 2023, in Prague, Czech Republic, and the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria, from September 9-13, 2023.

Key Points: 
  • Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs).
  • The study was carried out by Dr. Dongyoul Lee, an assistant professor at the Korea Military Academy.
  • The dose depositions in tumor and normal organs were estimated based on 203Pb biodistribution data.
  • In addition, tumor progression, survival rates, and body weight changes over a 120-day period were assessed, and favorable radiochemical characteristics were observed.

Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

Retrieved on: 
Tuesday, September 5, 2023

Revvity, Inc. (NYSE: RVTY) today debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems.

Key Points: 
  • Revvity, Inc. (NYSE: RVTY) today debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems.
  • These new innovations include the next-generation IVIS® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, further elevating versatility and sensitivity standards in in vivo optical imaging.
  • These cutting-edge technologies will be showcased at the World Molecular Imaging Congress (WMIC) being held September 5-9, in Prague, Czech Republic.
  • The system seamlessly integrates 2D optical and full 3D imaging, bolstered by high-throughput capabilities enabling simultaneous imaging of up to ten specimens.

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

Retrieved on: 
Wednesday, August 30, 2023

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two presentations at the upcoming World Molecular Imaging Congress (WMIC) 2023, hosted by the World Molecular Imaging Society (WMIS).

Key Points: 
  • RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two presentations at the upcoming World Molecular Imaging Congress (WMIC) 2023, hosted by the World Molecular Imaging Society (WMIS).
  • “We are pleased with our team’s progress in pioneering the development of promising image-guided, lead-based, alpha particle therapies.” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • Presenter: Michael K. Schultz, Ph.D., chief scientific officer, Perspective Therapeutics on behalf of Major Dr. Dongyoul Lee PhD, Assistant Professor, Korean Military Academy, Seoul, South Korea.
  • Additionally, a copy of the abstracts will be available on the Publications page of the Perspective Therapeutics website following the conference.

OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis

Retrieved on: 
Thursday, September 29, 2022

OncoNano Medicine, Inc. today announced positive interim clinical results from an ongoing Phase 2 study of its lead clinical development candidate, pegsitacianine, for the detection of residual disease following cytoreductive surgery (CRS).

Key Points: 
  • OncoNano Medicine, Inc. today announced positive interim clinical results from an ongoing Phase 2 study of its lead clinical development candidate, pegsitacianine, for the detection of residual disease following cytoreductive surgery (CRS).
  • The Phase 2 study ( NCT04950166 ) remains open to enrollment and is designed to evaluate the ability of pegsitacianine, a micellar fluorescence agent, to detect residual malignancies following CRS, an operation to completely resect peritoneal metastases.
  • The data presented revealed that 15 patients (55%) have demonstrated a clinically significant detection of pathology-confirmed residual disease following the completion of intended surgery.
  • Pegsitacianine is an intraoperative fluorescence imaging agent under development by OncoNano Medicine for the detection of cancerous tissue in patients undergoing surgical resection.

Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 World Molecular Imaging Congress (WMIC)

Retrieved on: 
Thursday, September 15, 2022

REDWOOD CITY, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics, today announced presentations of preclinical data on the selective uptake of its hydroxyl dendrimer-based PET tracer, [18F]OP-801, in the spines of a murine model of multiple sclerosis and a reduction in the PET signal after treatment with a hydroxyl dendrimer therapeutic (HDT) that inhibits CSF1 receptors. In addition, data on the synthesis of [18F]OP-801 suggests a reliable and high yielding method suitable for diagnostic imaging in humans. The data will be presented by scientific collaborators from Stanford University at the 2022 World Molecular Imaging Congress (WMIC), taking place at the Miami Beach Convention Center in Miami, FL, September 28 – October 1, 2022.

Key Points: 
  • In addition, data on the synthesis of [18F]OP-801 suggests a reliable and high yielding method suitable for diagnostic imaging in humans.
  • The data will be presented by scientific collaborators from Stanford University at the 2022 World Molecular Imaging Congress (WMIC), taking place at the Miami Beach Convention Center in Miami, FL, September 28 October 1, 2022.
  • Presentation details can be found below:
    [18F]OP-801 is a hydroxyl dendrimer (HD) imaging agent that provides information on uptake of HDs across tissue barriers including the blood-brain barrier.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Trellix Sees Advanced Persistent Threat Actors and Ransomware Groups Focus on Financial Services in Third Quarter of 2021

Retrieved on: 
Monday, January 31, 2022

Today, Trellix released its Advanced Threat Research Report: January 2022 , examining cybercriminal behavior and activity related to cyber threats in the third quarter of 2021.

Key Points: 
  • Today, Trellix released its Advanced Threat Research Report: January 2022 , examining cybercriminal behavior and activity related to cyber threats in the third quarter of 2021.
  • In Q3 2021, Trellix observed the resurgence of the DarkSide ransomware group as BlackMatter, despite that groups claim to have stopped operating.
  • Q3 2021 saw security operations tools like Cobalt Strike being abused by nation-state actors to gain access to their victims network.
  • The U.S. experienced the most reported incidents in Q3 2021, but incidents decreased 9% from Q2 2021.

Pegsitacianine Demonstrates Tumor-Agnostic Real-Time Surgical Imaging in Phase 2 Study

Retrieved on: 
Thursday, October 14, 2021

Pegsitacianine has previously been studied in a Phase 1 clinical trial where breast, head and neck, colorectal, and esophageal cancers were successfully imaged following an intravenous dose of pegsitacianine.

Key Points: 
  • Pegsitacianine has previously been studied in a Phase 1 clinical trial where breast, head and neck, colorectal, and esophageal cancers were successfully imaged following an intravenous dose of pegsitacianine.
  • The Phase 2 study results for pegsitacianine presented at the recent World Molecular Imaging Congress indicate this fluorescent nanoprobe has the potential to change the current surgical paradigm, said Dr. Newman.
  • The recently completed Phase 2 study (NCT03735680) was a non-randomized, open-label, multi-center study being conducted at three U.S. sites.
  • OncoNanos lead development candidate is pegsitacianine, a novel fluorescent nanoprobe, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries.

Ashvattha Therapeutics Announces Two Oral Presentations at the World Molecular Imaging Congress 2021

Retrieved on: 
Wednesday, September 29, 2021

Ashvattha Therapeutics , a clinical stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, neuro-oncology, and ophthalmology, today announced it will present two oral presentations at the virtual World Molecular Imaging Congress (WMIC), on October 5-8, 2021.

Key Points: 
  • Ashvattha Therapeutics , a clinical stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, neuro-oncology, and ophthalmology, today announced it will present two oral presentations at the virtual World Molecular Imaging Congress (WMIC), on October 5-8, 2021.
  • 18F-OP-801 is being developed as a companion diagnostic and also a pharmacodynamic tool for therapeutics to treat neuroinflammation.
  • Currently available imaging agents to detect neuroinflammation in Alzheimers and other neurodegenerative diseases have many limitations, including a lack of specificity.
  • Ashvattha Therapeutics, a clinical-stage biopharmaceutical company, is developing novel therapeutics that target and alter specific cells in areas of diseased tissues.

WMIS Awards Thomas Meade, PhD, the 2020 Gold Medal Award for Lifetime of Research in Cancer Imaging

Retrieved on: 
Friday, October 9, 2020

CULVER CITY, Calif., Oct. 9, 2020 /PRNewswire-PRWeb/ --The World Molecular Imaging Society (WMIS) awarded the 2020 Gold Medal Award to Thomas J. Meade, PhD, at Northwestern University, for his renowned dedication to the molecular imaging community and revolutionary contributions to the field.

Key Points: 
  • CULVER CITY, Calif., Oct. 9, 2020 /PRNewswire-PRWeb/ --The World Molecular Imaging Society (WMIS) awarded the 2020 Gold Medal Award to Thomas J. Meade, PhD, at Northwestern University, for his renowned dedication to the molecular imaging community and revolutionary contributions to the field.
  • Meade accepted the Gold Medal at the 13th annual World Molecular Imaging Congress (WMIC), October 7-9.
  • His address in acceptance of the Medal has been postponed to the WMIC annual meeting in Miami, October 6-10 of 2021.
  • He is the former President and founding member of the Society of Molecular Imaging and founder of Imaging in 2020, a biannual conference focusing on all aspects of imaging.

WMIS Presents 2018 Commercial Innovation of the Year Award to MILabs for VECTor-6 Broadband Photon Tomography

Retrieved on: 
Monday, October 15, 2018

MILabs was recognized for its latest innovation, VECTor-6 Broadband Photon Tomography, presented by Frederik Beekman, CEO/CSO, MILabs.

Key Points: 
  • MILabs was recognized for its latest innovation, VECTor-6 Broadband Photon Tomography, presented by Frederik Beekman, CEO/CSO, MILabs.
  • The WMIS community chooses the winner of the Commercial Innovation of the Year Award each year following presentations from 4-6 finalists at WMIC.
  • In addition to winning the 2018 award, MILabs was the recipient of the first-ever Commercial Innovation of the Year Award at WMIC 2015 in Hawaii for work in SPECT imaging.
  • The 5th annual Commercial Innovation of the Year Award will be given in Montral, Qubec, Canada at WMIC 2019.